LondonTransplant recipients face more than double the cancer death risk, researchers found.
Lifelong immunosuppression, needed to stop organ rejection, also disarms the immune system’s defence against tumors, the study noted.
Screening standards vary by country; no unified surveillance exists as more patients live longer on immunosuppression.
Sources: Nature